NewAmsterdam Pharma Q3 EPS $(0.14) Beats $(0.51) Estimate, Sales $19.164M Beat $7.340M Estimate
NewAmsterdam Pharma (NASDAQ:NAMS) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.51) by 72 percent. This is a 77.05 percent increase over losses of $(0.61) per share from
Share
Why It Matters
NewAmsterdam Pharma lost less money than experts thought it would. When a company shrinks its losses, it shows the business is getting stronger and more careful with spending.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.